
IgA Nephropathy Treatments Compared
7 FDA-approved drugs, plus 5 in development, side by side from the current prescribing labels. Newest label Oct 2026. Checked November 3, 2026.
The full IgA Nephropathy guide, with open trials and help paying →
Seven drugs are FDA-approved specifically for IgA nephropathy, all since December 2021, and they divide into 2 tiers.
- Tarpeyo, Filspari and Fabhalta hold full approval based on kidney function (eGFR) results on their labels, Tarpeyo to reduce the loss of kidney function and Filspari and Fabhalta to slow its decline.
- Vanrafia, Trutakna, Voyxact and Ultomiris hold accelerated approval based on lowering protein in the urine, and their labels say it is not yet established that they slow kidney decline.
- Trutakna and Voyxact have since reported positive 2-year eGFR results, and both companies have applied for full approval, Otsuka on October 22, 2026 and Vera on November 3, 2026.
- Vanrafia's final ALIGN results, published in The Lancet in June 2026, showed less kidney function loss than placebo at week 136, a difference that fell just short of statistical significance. Its yearly rate of decline was slower than on placebo, and Novartis has applied for full approval.
- Four are pills, Trutakna is a weekly self-injection, Voyxact is a self-injection every 4 weeks and Ultomiris, approved on October 21, 2026, is an IV infusion every 8 weeks.
- Povetacicept has an FDA decision due November 30, 2026, and 4 more drugs are in Phase 3, including Biohaven's BHV-1400, whose trial has not started enrolling yet.
Latest for IgA nephropathy
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Help payingThe Assistance Fund reopened its Immunoglobulin A Nephropathy (IgAN) fundTrial Friend
- FDA decisionFDA approved Ultomiris for IgA nephropathyFDA
Free email alert
Email me the day the FDA decides on Povetacicept
The FDA is due to decide by November 30th. You get one email when the decision is public, plus new trials and FDA news for this condition.
You'll get trial alerts and disease updates for IgA Nephropathy, and you can turn either off anytime. We never share your email. Privacy policy
7 approved IgA nephropathy treatments at a glance
How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.
A year on each IgA nephropathy treatment
Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.
Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.
What the pivotal IgA nephropathy trials showed
The primary result from the trial each FDA approval rests on, as reported on the label.
IgA Nephropathy treatment side effects and warnings
Filspari, Fabhalta, Vanrafia and Ultomiris carry a boxed warning, the FDA's strongest. The rest list their main precautions. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.
IgA nephropathy treatments in Phase 3 or under FDA review
Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.
Help paying for IgA nephropathy treatment
Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.
One email when the FDA acts on a IgA Nephropathy treatment, a label changes or a new trial opens. Never a newsletter.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
IgA Nephropathy treatment questions people ask
What is the best treatment for IgA nephropathy?
No trial has compared the 7 approved drugs with each other, so there is no evidence-based ranking. Tarpeyo, Filspari and Fabhalta have kidney function (eGFR) results from about 2 years of follow-up on their labels. Vanrafia, Trutakna, Voyxact and Ultomiris were approved on protein reduction and are still confirming kidney benefit. The right choice depends on how much protein is in the urine, kidney function, whether a pill or an injection fits your life, and whether you can stop ACE inhibitors or ARBs, which Filspari requires.
Which IgA nephropathy drugs are pills?
Tarpeyo (capsule once a day for 9 months), Filspari (tablet once a day), Fabhalta (capsule twice a day) and Vanrafia (tablet once a day). Trutakna is a shot under the skin once a week and Voyxact a shot every 4 weeks, both self-injected at home. Ultomiris is an IV infusion at a clinic every 8 weeks after a loading dose.
What new IgA nephropathy drugs are coming?
Ultomiris (ravulizumab) received accelerated approval, announced by AstraZeneca on October 21, 2026, and povetacicept has an FDA decision date of November 30, 2026. Sefaxersen met its Phase 3 primary endpoint in September 2026, and in October Roche reported 43.1% less urine protein than placebo at Week 37. Zigakibart's Phase 3 readout is expected in the first half of 2027 and felzartamab is in Phase 3. Biohaven said on October 29, 2026 that it is on track to start a Phase 3 trial of BHV-1400 in the fourth quarter of 2026. The pipeline table on this page lists each one with its trial.
Which IgA nephropathy treatments have a boxed warning?
Filspari, for liver injury and harm to a fetus; Vanrafia, for harm to a fetus; and Fabhalta, for serious infections caused by encapsulated bacteria, which requires vaccination before starting. Tarpeyo, Trutakna and Voyxact have no boxed warning. Ultomiris, approved for IgA nephropathy in October 2026, carries a boxed warning for serious meningococcal infections and is available only through a safety program.
Does Tarpeyo cure IgA nephropathy?
No. Tarpeyo is a 9-month course of a targeted-release steroid that, in its trial, left kidney function 5.9mL/min/1.73 m2 better than placebo at 2 years and lowered urine protein by 31% more than placebo at 9 months. The kidney function benefit held after the course ended, but the label notes it did not change the long-term rate of decline, and the disease itself is not removed.
More on IgA Nephropathy at Trial Friend
Where every number on this page comes from
Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.
- Tarpeyo (budesonide delayed-release capsules) prescribing information, Calliditas Therapeutics, label dated Jan 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Filspari (sparsentan) prescribing information, Travere Therapeutics, label dated Apr 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Fabhalta (iptacopan) prescribing information, Novartis, label dated Jul 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Vanrafia (atrasentan) prescribing information, Novartis, label dated Jun 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Trutakna (atacicept-vymj) prescribing information, Vera Therapeutics, label dated Aug 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Voyxact (sibeprenlimab-szsi) prescribing information, Otsuka, label dated Mar 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Ultomiris (ravulizumab-cwvz) prescribing information, Alexion (AstraZeneca), label dated Oct 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- povetacicept, Vertex Pharmaceuticals (Alpine Immune Sciences): ClinicalTrials.gov record; Vertex press release, June 1, 2026. Checked October 1, 2026.
- sefaxersen, Roche (licensed from Ionis): ClinicalTrials.gov record; Roche media release, October 23, 2026. Checked October 23, 2026.
- zigakibart, Novartis: ClinicalTrials.gov record; Novartis Q2 2026 media release, July 21, 2026. Checked October 1, 2026.
- felzartamab, Biogen: ClinicalTrials.gov record; ClinicalTrials.gov NCT06935357, updated October 14, 2026. Checked November 3, 2026.
- BHV-1400, Biohaven: ClinicalTrials.gov record; Biohaven Q3 2026 release, October 29, 2026. Checked November 3, 2026.
This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.